Komori
Ono Pharmaceutical (4528) · InitiativeAdvancedLatest Governance (2026-09-30): "Restated"

Establishment of company-wide internal control and risk response structures

First written in FY2016. 4 of 8 entries say "Advanced", first in FY2020. Latest entry: 2026-09-30.

8entries
11years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY2018AdvancedFY2020 – 2026-05-212016: 120162017: 120172018: 120182019: 020192020: 120202021: 020212022: 120222023: 020232024: 120242025: 020252026: 22026
Same theme, other companies
Group-wide ERM and risk management frameworkA theme 263 companies write about · 4 as a headwind · 202 as a tailwind

80 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 265 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024AdvancedAnnual report

    「Risks rated “high” or above are classified as “key risks.” Departmental risk management officers at the division head or general manager level act as risk owners, taking responsibility for cross-functional response measures and promoting ERM more closely integrated with management.」

    ERM procedures have been made specific through identification of key risks, designation of risk owners, and cross-functional response measures and monitoring.
  2. FY2022AdvancedAnnual report

    「To promote ERM, we interviewed members of senior management and identified the risks they considered important. We then evaluated and classified the risks in workshops with risk managers selected from each division. In the workshops, risks identified by senior management and those brought by each manager were discussed together with scenarios that could actually occur. The frequency of occurrence was assessed on a 7-point scale and the severity of the impact if the risk occurred on a 5-point scale, from which risk indices were derived and each risk was classified as very high, high, medium or low.」

    ERM procedures have been made specific, including risk managers, scenario analysis, assessment using a 7-point occurrence-frequency scale and a 5-point impact-severity scale, and designation of those responsible for responses.
  3. FY2020AdvancedAnnual report

    「Aiming for risk management that optimizes the organization as a whole rather than individual parts, we began preparations to introduce ERM (Enterprise Risk Management) in fiscal 2018 and introduced it in fiscal 2019. In connection with its introduction, we appointed a Chief Risk Management Officer, the Representative Director and President, and an Executive Officer responsible for overall risk management, the Director and Senior Managing Executive Officer/Head of the Corporate Strategy Division. We also newly established the Risk Management Office, enacted the Risk Management Regulations, and are promoting ERM.」

    The company’s specific preparations for ERM are described, including its introduction in fiscal 2019, appointment of those responsible, establishment of the Risk Management Office and enactment of regulations.
  4. FY2018RestatedAnnual report

    「Risk management relating to compliance, product quality and safety, occupational health and safety, the environment, disasters and information security is addressed by the relevant departments through the preparation and distribution of procedures, training and other measures based on internal rules for each area.」

    A company-wide internal control policy based on internal rules, procedures, training, meeting bodies and emergency response for each risk area has been reaffirmed.
  5. FY2017RestatedAnnual report

    「Risk management relating to compliance, product quality and safety, occupational health and safety, the environment, disasters and information security is addressed by the relevant departments through the preparation and distribution of procedures, training and other measures based on internal rules for each area.」

    A company-wide response structure based on internal rules, procedures, training, meeting bodies and emergency response committees for each risk area has been reaffirmed.
  6. FY2016First statedAnnual report

    「Risk management relating to compliance, product quality and safety, occupational health and safety, the environment, disasters and information security is addressed by the relevant departments through the preparation and distribution of procedures, training and other measures based on internal rules for each area.」

    A response structure has been established for each risk area through internal rules, procedures, training, meeting bodies and emergency response committees.
Moved together

"Expansion of the development pipeline and continued launches of new drugs" moved the same way as this thread, in the same document, in 3 of its 8 moves.

333333★123456
  1. ★This thread
  2. 1Expansion of the development pipeline and continued launches of new drugs3×
  3. 2In-Licensing Promising New Drug Candidate Compounds and Accelerating Clinical Trials3×
  4. 3Drug Discovery Collaborations with Universities, Research Institutions and Biotech Ventures3×
  5. 4Holding Shares to Maintain and Strengthen Business Relationships3×
  6. 5Development and Sales Milestone Payment Obligations3×
  7. 6Medium-term targets for the R&D investment ratio and operating margin3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview It last moved in the Governance of 2026-09-30: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Establishment of company-wide internal control and risk response structures | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori